Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
13 Giugno 2024 - 5:00PM
Zealand Pharma Increases its Share Capital as a Consequence of
Exercise of Employee Warrants
Company announcement – No. 31 / 2024
Zealand Pharma Increases its Share Capital as a
Consequence of Exercise of Employee Warrants
Copenhagen, Denmark, June 13, 2024 – Zealand
Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a
Copenhagen-based biotechnology company focused on the discovery and
development of innovative peptide-based medicines, has increased
its share capital by a nominal amount of DKK 2,750 divided into
2,750 new shares with a nominal value of DKK 1 each. The increase
is a consequence of the exercise of warrants granted under several
of Zealand Pharma's employee warrant programs.
Employee warrant programs are part of Zealand Pharma’s incentive
scheme, and each warrant gives the owner the right to subscribe for
one newly issued Zealand Pharma share at a prespecified price, the
exercise price, in specific predefined time periods before
expiration. For a more detailed description of Zealand Pharma’s
warrant programs, see the company’s Articles of Association, which
are available on the website: www.zealandpharma.com.
The exercise price was DKK 224.40 per share for 2,750 of new
shares. The total proceeds to Zealand from the capital increase
amount to DKK 617,100.00.
The new shares give rights to dividend and other rights from the
time of the warrant holder's exercise notice. Each new share
carries one vote at Zealand Pharma’s general meetings. Zealand
Pharma has only one class of shares.
The new shares will be listed on Nasdaq Copenhagen after
registration of the capital increase with the Danish Business
Authority. Following registration of the new shares, the share
capital of Zealand Pharma will be nominal DKK 62,650,761 divided
into 62,650,761 shares with a nominal value of DKK 1 each.
A full copy of the amended Articles of Association can be found
at https://www.zealandpharma.com once registered with the Danish
Business Authority.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is
a biotechnology company focused on the discovery and development of
peptide-based medicines. More than 10 drug candidates invented by
Zealand have advanced into clinical development, of which two have
reached the market and three candidates are in late-stage
development. The company has development partnerships with a number
of blue-chip pharma companies as well as commercial partnerships
for its marketed products.
Zealand was founded in 1998 and is headquartered
in Copenhagen, Denmark, with a presence in the U.S. that includes
Boston. For more information about Zealand’s business and
activities, please visit www.zealandpharma.com.
Contact:Anna Krassowska, PhDVice President,
Investor Relations & Corporate CommunicationsZealand
PharmaEmail: ank@zealandpharma.com
Adam Lange Investor Relations OfficerZealand PharmaEmail:
akl@zealandpharma.com
Grafico Azioni Zealand Pharma AS (TG:22Z)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Zealand Pharma AS (TG:22Z)
Storico
Da Dic 2023 a Dic 2024
